Key result
Adenovirus-vectored vaccines represent a promising platform for mucosal immunization against pathogens like Mycobacterium tuberculosis, influenza, and HIV, despite challenges with preexisting immunity.
Adenoviral-vectored vaccines represent a promising platform for mucosal immunization against intracellular infectious diseases.
May support mucosal vaccine trials for TB, influenza, and HIV; leaves open translation amid preexisting immunity.
Adenoviruses represent the most widely used viral-vectored platform for vaccine design, showing a great potential in the fight against intracellular infectious diseases to which either there is a lack of effective vaccines or the traditional vaccination strategy is suboptimal. The extensive understanding of the molecular biology of adenoviruses has made the new technologies and reagents available to efficient generation of adenoviral-vectored vaccines for both preclinical and clinical evaluation. The novel adenoviral vectors including nonhuman adenoviral vectors have emerged to be the further improved vectors for vaccine design. In this review, we discuss the latest adenoviral technologies and their utilization in vaccine development. We particularly focus on the application of adenoviral-vectored vaccines in mucosal immunization strategies against mucosal pathogens including Mycobacterium tuberculosis, flu virus, and human immunodeficiency virus.
No takes yet. Share an insight, caveat, or question.
Afkhami et al. (2016) conducted a review in Mucosal pathogens (Tuberculosis, Influenza, HIV). Adenovirus-vectored vaccines was evaluated. Adenovirus-vectored vaccines represent a promising platform for mucosal immunization against pathogens like Mycobacterium tuberculosis, influenza, and HIV, despite challenges with preexisting immunity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: